Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Lercanidipine, a newer-generation calcium channel blocker, is recognized for its effective antihypertensive properties and reduced side effects. This study aims to compare the effectiveness of lercanidipine and amlodipine in preventing major adverse cardiovascular events (MACE) in hypertensive patients.
Methods: A multicenter, retrospective observational study was conducted using the electronic medical records database from 3 tertiary hospitals in South Korea between 2017 and 2021. Hypertensive patients treated with either amlodipine or lercanidipine were analyzed. Propensity score matching (PSM) was utilized to minimize confounders, matching patients in a 3:1 ratio. The primary endpoint was the incidence of MACE, a composite of cardiovascular death, myocardial infarction, stroke, heart failure hospitalizations, and coronary revascularization over a 3-year follow-up period.
Results: A total of 47,640 patients were evaluated, and 6,029 patients were matched. Before PSM, the lercanidipine group had a higher cardiovascular risk (SCORE-2/SCORE-2OP value: 11.6% ± 9.2 vs. 10.9% ± 8.8, P < 0.01) and a higher incidence of MACE compared to the amlodipine group (4.1% vs. 3.4%, P < 0.01). After PSM, the incidence of MACE was numerically lower in the lercanidipine group compared to the amlodipine group (2.8% vs. 4.1%, P = 0.11), though this difference was not statistically significant. Blood pressure control remained comparable between the 2 groups over the 3-year follow-up period.
Conclusions: Lercanidipine demonstrated comparable effectiveness to amlodipine in preventing MACE among hypertensive patients. Given its comparable antihypertensive efficacy and potential for fewer side effects based on prior studies, lercanidipine may be considered a preferable option for hypertension management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajh/hpae147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Choosing the right calcium channel blocker for patients with hypertension and proteinuric chronic kidney disease.
Curr Med Res Opin
July 2025
Nephrology and Dialysis Unit, Department of Systems Medicine, Policlinico Tor Vergata Hospital, Rome, Italy.
Arterial hypertension and diabetes mellitus represent major modifiable risk factors for the occurrence of cardiovascular disease, development of chronic kidney disease (CKD) and progression of CKD to end-stage renal disease (ESRD). In view of the rising burden of hypertension, diabetes mellitus and CKD on a global scale, there is currently a great need for drugs that can effectively prevent the onset and reverse or slow down the progression of CKD in diverse patient populations. Over the last decades, a growing body of evidence has demonstrated that calcium channel blockers (CCBs) can exert cardioprotective and nephroprotective actions.
View Article and Find Full Text PDFLercanidipine Enhances Cisplatin Activity: Dual Anticancer and Anti-Inflammatory Effects via Caspase Activation and MAPK Inhibition.
Pharmaceuticals (Basel)
April 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Okan University, İstanbul 34959, Türkiye.
: Lercanidipine is a third-generation dihydropyridine calcium channel blocker. In addition to their well-established cardiovascular effects, calcium channel blockers are increasingly recognized for their therapeutic potential in various cancers. This study aimed to investigate the potential anticancer effects of lercanidipine on cancer cell lines-particularly in combination with cisplatin-by assessing parameters such as cell viability (MTT assay), proliferation, MAPK pathway activity, caspase enzyme levels, and TNF-α expression.
View Article and Find Full Text PDFLooks are deceiving: An uncommon cause of milky white peritoneal dialysis effluent.
Perit Dial Int
September 2025
Department of Nephrology, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Peritoneal dialysis effluent should be clear and any changes in aspect require further investigation. We report a case of a spontaneous milky white effluent (chyloperitoneum) associated with calcium channel blockers in a peritoneal dialysis patient. Our case is a 43-year-old man that presents with milky white peritoneal dialysis effluent 9 days after starting peritoneal dialysis.
View Article and Find Full Text PDFUHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists' drugs in human plasma.
Biomed Pharmacother
March 2025
Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin 10149, Italy.
One of the principal challenges in managing hypertension is suboptimal medication adherence, which can result in up to 50 % of patients experiencing pseudo-resistant hypertension and inadequate blood pressure control. The intricate nature of antihypertensive regimens, the high cost of therapy, the prevalence of numerous adverse effects and the therapeutic inertia commonly lead to inconsistent drug use and premature discontinuation of treatment. Consequently, nonadherence significantly elevates the risk of cardiovascular events.
View Article and Find Full Text PDFEffects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Public and Occupational Health, Amsterdam Public health Research Institute, Amsterdam university Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Article Synopsis
- Chronic inflammation, particularly the role of interleukin-6 (IL-6), is being explored as a target for improving hypertension treatment.
- In a study involving 1,510 participants over six years, it was found that calcium channel blockers (CCBs) with IL-6-lowering properties (specifically amlodipine and barnidipine) resulted in better blood pressure control compared to other CCBs.
- No significant differences were seen in blood pressure control among other antihypertensive classes or across different ethnic groups, indicating a need for further research into IL-6's impact on hypertension management.